Concepedia

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

Stanley I. Martin, Francisco M. Marty, Karen Fiumara, Steven P. Treon, John G. Gribben, Lindsey R. Baden

Clinical Infectious Diseases · 2006 · 270 citations · 22 references

DOI

Abstract

Despite the use of herpesvirus and Pneumocystis pneumonia prophylaxis, serious infectious complications occur in patients receiving alemtuzumab for lymphoproliferative disorders. Infectious complications are more varied and diverse in patients receiving alemtuzumab than has been reported in trials to date.

References

22

Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus

John Rex, Ben de Pauw, John E. Bennett et al. · Clinical Infectious Diseases · 2002 · 2.3K citations · Full text

, , +16

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Michael J. Keating, Ian W. Flinn, Vinay Jain et al. · Blood · 2002 · 946 citations · Full text

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Anders Österborg, Martin J.S. Dyer, Donald Bunjes et al. · Journal of Clinical Oncology · 1997 · 517 citations

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 496 citations · Full text

RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)

Allan D. Kirk, Douglas A. Hale, Roslyn B. Mannon et al. · Transplantation · 2003 · 436 citations